Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17302256 | 0.80 | PRMT5 (0.30) | — | |
| SCHEMBL17549898 | 0.75 | PRMT5 (0.38) | ADK | |
| SCHEMBL17549901 | 0.74 | HTR2B (0.33) | ADK | |
| SCHEMBL17549902 | 0.74 | HTR2B (0.38) | ADK | |
| SCHEMBL15381061 | 0.72 | AHCY (0.38) | ADK | |
| SCHEMBL15381065 | 0.71 | NNMT (0.35) | ADK | |
| SCHEMBL17302255 | 0.71 | PRMT5 (0.41) | — | |
| SCHEMBL23120133 | 0.70 | PRMT5 (0.42) | ADK | |
| SCHEMBL17302276 | 0.68 | PRMT5 (0.34) | ADK | |
| SCHEMBL17936459 | 0.68 | PRMT5 (0.34) | ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458165-B2 | DOT1L inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458165-B2 | DOT1L inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160060269-A1 | DOT1L Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160060269-A1 | DOT1L Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060269-A1 | DOT1L Inhibitors | DOT1L, MAP1LC3B, MAP1LC3A | ADK 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.